These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19877499)

  • 1. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment.
    Müller N; Myint AM; Schwarz MJ
    Dialogues Clin Neurosci; 2009; 11(3):319-32. PubMed ID: 19877499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2 inhibition in schizophrenia and major depression.
    Müller N; Schwarz MJ
    Curr Pharm Des; 2008; 14(14):1452-65. PubMed ID: 18537668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
    Müller N
    Curr Opin Investig Drugs; 2010 Jan; 11(1):31-42. PubMed ID: 20047157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological treatment options for schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1606-13. PubMed ID: 22283758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune System and Schizophrenia.
    Müller N; Schwarz MJ
    Curr Immunol Rev; 2010 Aug; 6(3):213-220. PubMed ID: 21057585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory treatment in schizophrenia.
    Müller N; Myint AM; Krause D; Weidinger E; Schwarz MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():146-53. PubMed ID: 23178230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
    Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
    Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Adv Protein Chem Struct Biol; 2012; 88():49-68. PubMed ID: 22814706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.
    Miüller N; Schwarz MJ
    J Neural Transm Suppl; 2007; (72):269-80. PubMed ID: 17982903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory biomarkers and depression.
    Müller N; Myint AM; Schwarz MJ
    Neurotox Res; 2011 Feb; 19(2):308-18. PubMed ID: 20658274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.
    Müller N; Schwarz MJ
    Eur Arch Psychiatry Clin Neurosci; 2008 Jun; 258 Suppl 2():97-106. PubMed ID: 18516521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.
    Müller N; Schwarz MJ
    Mol Psychiatry; 2007 Nov; 12(11):988-1000. PubMed ID: 17457312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
    Myint AM; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
    Muller N; Schwarz M
    Neurotox Res; 2006 Oct; 10(2):131-48. PubMed ID: 17062375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunological treatment options for schizophrenia].
    Müller N; Krause D; Weidinger E; Schwarz M
    Fortschr Neurol Psychiatr; 2014 Apr; 82(4):210-9. PubMed ID: 24710677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection.
    Stone TW
    Trends Pharmacol Sci; 2000 Apr; 21(4):149-54. PubMed ID: 10740291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders.
    Müller N; Schwarz MJ
    Expert Rev Neurother; 2006 Jul; 6(7):1017-38. PubMed ID: 16831116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kynurenic acid antagonists and kynurenine pathway inhibitors.
    Stone TW
    Expert Opin Investig Drugs; 2001 Apr; 10(4):633-45. PubMed ID: 11281814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological aspects of the treatment of depression and schizophrenia.
    Müller N
    Dialogues Clin Neurosci; 2017 Mar; 19(1):55-63. PubMed ID: 28566947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.